New drugs that can help in treatment of amyloidosis of diverse origins

Place of work — National
Amyloidosis Centre,
University College of
London, UK
Contacts — Rowland Hill Street, London NW3 2PF, UK +44 (20) 7433–2815 p.n.hawkins@rfc.ucl.ac.uk
Publications — Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Nature. 2002 May 16;417(6886):254–9.
Molecular dissection of Alzheimer’s disease neuropathology by depletion of serum amyloid P component. Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7619–23.
Novel pharmacological strategies in amyloidosis. Lachmann HJ, Hawkins PN. Nephron Clin Pract. 2003;94(4):c85-8.